LGI1 Antibody

LGI1 Antibody: The leucine-rich, glioma inactivated gene 1 (LGI1) was first identified as a candidate tumor suppressor gene for glioma and may play a role in other cancers. LGI1 is a member of a family of highly related proteins containing leucine-rich repeats (LRRs) which are highly similar to other transmembrane signaling molecules and receptors. LGI1 serves as a ligand to ADAM22, a metalloprotease localized at the synapse. Mutations in LGI1 account for nearly half of autodominant lateral temporal epilepsy (ADTLE), an epileptic syndrome characterized by focal seizures with predominant auditory symptoms. Two isoforms of LGI1 are known to exist, but the top band seen in the western blot is likely to be non-specific. This LGI1 antibody is predicted to be specific to LGI1 and not recognize other LGI proteins.

LGI1 antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Chernova OB, Somerville RP and Cowell JK. A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors. Oncogene1998; 17:2873-81.

Fialka F, Gruber RM, Hitt R, et al. CPA6, FMO2, LGI1, SIAT1 and TNC are differentially expressed in early- and late-stage oral squamous cell carcinoma - A pilot study. Oral Oncol.2008

Gu W, Gibert Y, Wirth T, et al. Using gene-history and expression analysis to assess the involvement of LGI genes in human disorders. Mol. Biol. Evol.2005; 22:2209-16.

Fukata Y, Adesnik H, Iwanaga T, et al. Epilepsy-related ligand/receptor complex LGI1 and ADAM22 regulate synaptic transmission. Science2006; 313:1792-5.